Lexeo Therapeutics Statistics
Total Valuation
LXEO has a market cap or net worth of $398.73 million. The enterprise value is $193.83 million.
| Market Cap | 398.73M |
| Enterprise Value | 193.83M |
Important Dates
The last earnings date was Wednesday, August 12, 2026, before market open.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
LXEO has 82.04 million shares outstanding. The number of shares has increased by 113.19% in one year.
| Current Share Class | 82.04M |
| Shares Outstanding | 82.04M |
| Shares Change (YoY) | +113.19% |
| Shares Change (QoQ) | +5.47% |
| Owned by Insiders (%) | 0.37% |
| Owned by Institutions (%) | 78.10% |
| Float | 51.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.63 |
| P/TBV Ratio | 1.70 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.89, with a Debt / Equity ratio of 0.03.
| Current Ratio | 13.89 |
| Quick Ratio | 13.57 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,302.97 |
Financial Efficiency
Return on equity (ROE) is -46.76% and return on invested capital (ROIC) is -30.56%.
| Return on Equity (ROE) | -46.76% |
| Return on Assets (ROA) | -27.59% |
| Return on Invested Capital (ROIC) | -30.56% |
| Return on Capital Employed (ROCE) | -39.76% |
| Weighted Average Cost of Capital (WACC) | 12.11% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.39M |
| Employee Count | 63 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +0.21% in the last 52 weeks. The beta is 1.46, so LXEO's price volatility has been higher than the market average.
| Beta (5Y) | 1.46 |
| 52-Week Price Change | +0.21% |
| 50-Day Moving Average | 4.75 |
| 200-Day Moving Average | 6.51 |
| Relative Strength Index (RSI) | 50.52 |
| Average Volume (20 Days) | 927,403 |
Short Selling Information
The latest short interest is 20.48 million, so 24.96% of the outstanding shares have been sold short.
| Short Interest | 20.48M |
| Short Previous Month | 17.05M |
| Short % of Shares Out | 24.96% |
| Short % of Float | 39.98% |
| Short Ratio (days to cover) | 20.34 |
Income Statement
| Revenue | n/a |
| Gross Profit | -66.64M |
| Operating Income | -95.12M |
| Pretax Income | -87.27M |
| Net Income | -87.27M |
| EBITDA | -94.50M |
| EBIT | -95.12M |
| Earnings Per Share (EPS) | -$1.15 |
Balance Sheet
The company has $211.70 million in cash and $6.81 million in debt, with a net cash position of $204.89 million or $2.50 per share.
| Cash & Cash Equivalents | 211.70M |
| Total Debt | 6.81M |
| Net Cash | 204.89M |
| Net Cash Per Share | $2.50 |
| Equity (Book Value) | 235.06M |
| Book Value Per Share | 2.99 |
| Working Capital | 202.22M |
Cash Flow
In the last 12 months, operating cash flow was -$88.37 million and capital expenditures -$331,000, giving a free cash flow of -$88.70 million.
| Operating Cash Flow | -88.37M |
| Capital Expenditures | -331,000 |
| Depreciation & Amortization | 613,000 |
| Net Borrowing | -515,000 |
| Free Cash Flow | -88.70M |
| FCF Per Share | -$1.08 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LXEO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -113.19% |
| Shareholder Yield | n/a |
| Earnings Yield | -21.89% |
| FCF Yield | -22.25% |
Analyst Forecast
The average price target for LXEO is $20.30, which is 317.70% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $20.30 |
| Price Target Difference | 317.70% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |